Abstract: A sequence of the FMR-1 gene is disclosed. This sequence and related probes, cosmids and unique repeats are used to detect X-linked diseases and especially the fragile X syndrome.
Type:
Grant
Filed:
May 24, 1991
Date of Patent:
August 22, 2000
Assignee:
Baylor College of Medicine
Inventors:
C. Thomas Caskey, David L. Nelson, Maura Pieretti, Stephen T. Warren, Ben A. Oostra
Abstract: A method for the detection of a polynucleotide target sequence is described. The method involves the formation of a covalent or non-covalent bonded pair of nucleotide sequences formed in response to a target polynucleotide sequence, adding nucleotide sequence specific binding proteins each capable of binding one member of the pair of nucleotide sequences, and detecting the specific binding proteins complexed to the pair of nucleotide sequences.
Abstract: Systems and methods for aligning scanned images are provided. A pattern is included in the scanned image so that when the image is convolved with a filter, a recognizable pattern is generated in the convolved image. The scanned image may then be aligned according to the position of the recognizable pattern in the convolved image. The filter may also act to remove the portions of the scanned image that do not correspond to the pattern in the scanned image.
Abstract: The present invention relates to a process for detecting the presence of at least one specific nucleic acid sequence in a sample containing a nucleic acid or a mixture of nucleic acids by amplifying the nucleic acid using polymerase chain reaction, cleaving the amplified products with uracil DNA glycosylase to obtain short DNA segments and detecting the DNA fragments by using reverse blot hybridization.
Abstract: Methods for amplifying target nucleic acid sequences using a nucleic acid polymerase lacking 5' exonuclease activity and a set of oligonucleotide primers. Preferably, a primer array is used. The primer array contains two sets of primers. One set contains at least two complementary primers. The other set contains at least two sense primers. Using the described methods amplification can be carried out under essentially constant environmental conditions without the requirement for exonuclease activity or restriction endonuclease activity.
Type:
Grant
Filed:
November 18, 1997
Date of Patent:
July 11, 2000
Assignee:
Gen-Probe Incorporated
Inventors:
Nanibhushan Dattagupta, Paul Douglas Stull, Marc Spingola, Daniel Louis Kacian
Abstract: The present invention provides labeled synthetic libraries of random oligomers and methods and apparatus for generating labeled synthetic oligomer libraries. Each member of such a library is labeled with a unique identifier tag that specifies the structure or sequence of the oligomer. In a preferred embodiment of the present invention the identifier tag is a microchip that is pre-encoded or encodable with information that is related back to a detector when the identifier tag is pulsed with electromagnetic radiation.
Abstract: New mutations have been found in the BRCA1 gene. The mutations are located at nucleotide numbers 421-2, 815, 903, 926, 1506, 2034, 2428, 3888, 3904, 4164, 4643, 5053, 5150, 5210, or 5396+40 of the gene sequence of BRCA1. A process for identifying a sequence variation in a BRCA1 polynucleotide sequence is disclosed. The identification process includes allele specific sequence-based assays of known sequence variations. The methods can be used for efficient, and accurate detection of a mutation in a test BRCA1 gene sample.
Type:
Grant
Filed:
December 11, 1997
Date of Patent:
July 4, 2000
Assignee:
Oncormed, Inc.
Inventors:
Sheri Jon Olson, Tracy Staton Angelly, Tammy Lawrence, Jennifer Lee Lescallett, Patricia Davis Murphy, Antonette Preisinger Allen, Denise Bernadette Thurber, Marga Belle White, Bin Zeng, Lisa K. Sadzewicz
Abstract: A method is described for generating blended nucleic acid ligands containing non-nucleic acid functional units. Specifically, a SELEX identified RNA ligand to the integrin gpIIbIIIa is conjugated to the peptide Gly-Arg-Gly-Asp-Thr-Pro (SEQ ID NO:1). This blended RNA ligand inhibits the biological activity of gpIIbIIIa with high specificity. Also described is a single-stranded DNA ligand to elastase coupled to N-methoxysuccinyl-Ala-Ala-Pro-Val-chloromethyl (SEQ ID NO:3) ketone. This elastase blended nucleic acid ligand inhibits the biological activity of elastase.
Type:
Grant
Filed:
October 23, 1997
Date of Patent:
July 4, 2000
Assignee:
NeXstar Pharmaceuticals, Inc.
Inventors:
Greg Biesecker, Sumedha D. Jayasena, Larry Gold, Drew Smith, Gary Kirschenheuter
Abstract: The invention relates to the isolation of a nucleic acid molecule which encodes an esophageal cancer associated antigen. Also a part of the invention is the antigen itself, and the uses of the nucleic acid molecule and the antigen.
Type:
Grant
Filed:
January 26, 1998
Date of Patent:
May 30, 2000
Assignees:
Memorial Sloan-Kettering Cancer Center, Cornell Research Foundation, Ludwig Institute for Cancer Research
Inventors:
Yao-tseng Chen, Matthew Scanlan, Ali O. Gure, Lloyd J. Old, Ozlem Tureci, Ugur Sahin, Michael Pfreundschuh
Abstract: This invention provides a method of detecting metastatic thyroid cancer in a subject which comprises detecting circulating thyroid cells in a bodily fluid sample of the subject by obtaining an appropriate nucleic acid sample from the bodily fluid sample of the subject; and determining whether the nucleic acid sample contains a marker sequence. Specifically, this invention provides wherein the marker sequence is mRNA corresponding to the reverse transcript of DNA encoding thyroglobulin. Also, this invention provides wherein the marker sequence is mRNA corresponding to the reverse transcript of DNA encodes thyroid peroxidase. This invention further provides a test kit for performing the above-described method.
Type:
Grant
Filed:
April 15, 1997
Date of Patent:
May 23, 2000
Assignee:
The Trustees of Columbia University in the City of New York
Inventors:
Beth Ann Ditkoff, John A. Chabot, Carl R. Feind, Paul LoGerfo
Abstract: A computer system for analyzing nucleic acid sequences is provided. The computer system is used to calculate probabilities for determining unknown bases by analyzing the fluorescence intensities of hybridized nucleic acid probes on biological chips. Additionally, information from multiple experiments is utilized to improve the accuracy of calling unknown bases.
Abstract: A method for the detection of a polynucleotide target sequence is described. The method involves the formation of a covalent or non-covalent bonded pair of nucleotide sequences formed in response to a target polynucleotide sequence, adding nucleotide sequence specific binding proteins each capable of binding one member of the pair of nucleotide sequences, and detecting the specific binding proteins completed to the pair of nucleotide sequences.
Abstract: Hepatitis GB Virus (HGBV) nucleic acid and amino acid sequences useful for a variety of diagnostic and therapeutic applications, kits for using the HGBV nucleic acid or amino acid sequences, HGBV immunogenic particles, and antibodies which specifically bind to HGBV. Also provided are methods for producing antibodies, polyclonal or monoclonal, from the HGBV nucleic acid or amino acid sequences.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
April 18, 2000
Assignee:
Abbott Laboratories
Inventors:
John N. Simons, Tami J. Pilot-Matias, George J. Dawson, George G. Schlauder, Suresh M. Desai, Thomas P. Leary, Anthony Scott Muerhoff, James Carl Erker, Sheri L. Buijk, Isa K. Mushahwar
Abstract: This invention discloses a method for preparing a complex comprised of a VEGF Nucleic Acid Ligand and a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound by identifying a VEGF Nucleic Acid Ligand by SELEX methodology and associating the VEGF Nucleic Acid Ligand with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further discloses Complexes comprising one or more VEGF Nucleic Acid Ligands in association with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further includes a Lipid construct comprising a VEGF Nucleic Acid Ligand or Complex and methods for making the same.
Type:
Grant
Filed:
July 21, 1997
Date of Patent:
April 18, 2000
Inventors:
Nebojsa Janjic, Larry Gold, Paul Schmidt, Chandra Vargeese
Abstract: Methods of diagnosing glaucoma, and particularly primary congenital glaucoma, by detecting mutations in a gene associated with glaucoma, such as the CYP1B1 gene, are disclosed. Methods include hybridization analysis, such as Southern or Northern analysis, which use hybridization of a mutant nucleic acid probe to the gene associated with glaucoma; direct mutation analysis by restriction digest; sequencing of the gene associated with glaucoma; hybridization of an allele-specific oligonucleotide with amplified genomic DNA; or identification of the presence of mutant proteins encoded by the gene associated with glaucoma. Kits for use in diagnosis of glaucoma are also described. Methods of treatment of glaucoma, including administration of the protein encoded by the gene associated with glaucoma; administration of genes, gene constructs, or other nucleic acid constructs; or administration of other therapeutic agents, are additionally described.
Abstract: The cDNA sequence of the ALL-1 gene on chromosome 11 is provided. A partial sequence of the AF-4 gene is also provided in the context of the sequences of two reciprocal endproducts of a translocation. Amino acid sequences corresponding to the cDNA sequences of the entire ALL-1 gene and the partial sequence of the AF-4 gene, and sequences relating to chimeric genes formed by chromosome translocations with chromosome 4, 9 and 19, respectively, are provided. Probes are provided for detecting chromosome abnormalities involving the ALL-1 gene on chromosome 11, including probes for detecting chimeric genes generated by translocations. Monoclonal antibodies for diagnosis and treatment and antisense oligonucleotides for treatment of acute leukemias are also described.
Abstract: This invention discloses a method for coevolving products from two or more reactants, along with the nucleic acid that can facilitate the reaction for making the products. The invention further discloses the products and facilitating nucleic acids produced by said method.
Abstract: Methods are described for the identification and preparation of high-affinity nucleic acid ligands to cytokines. Included in the invention are specific nucleic acid ligands to IFN-gamma, IL-4, IL-10, TNF-alpha, and RANTES.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
February 22, 2000
Assignee:
NeXstar Pharmaceuticals, Inc.
Inventors:
Diane Tasset, Nikos Pagratis, Sumedha Jayasena, Larry Gold
Abstract: Combinations, called matrices with memories, of matrix materials with remotely addressable or remotely programmable recording devices that contain at least one data storage unit are provided. The matrix materials are those that are used in as supports in solid phase chemical and biochemical syntheses, immunoassays and hybridization reactions. The matrix materials may additionally include fluophors or other luminescent moieties to produce luminescing matrices with memories. The data storage units are non-volatile antifuse memories or volatile memories, such as EEPROMS, DRAMS or flash memory. By virtue of this combination, molecules and biological particles, such as phage and viral particles and cells, that are in proximity or in physical contact with the matrix combination can be labeled by programming the memory with identifying information and can be identified by retrieving the stored information. Combinations of matrix materials, memories, and linked molecules and biological materials are also provided.
Type:
Grant
Filed:
December 5, 1995
Date of Patent:
February 15, 2000
Assignee:
Irori
Inventors:
Michael P. Nova, Andrew E. Senyei, Zahra Parandoosh, Gary S. David
Abstract: The gene for the autosomal recessive neurodegenerative disorder Spinal Muscular Atrophy has been mapped to a region of chromosome 5. The gene encodes a protein having homology with apoptosis inhibitor proteins of viruses so that the encoded protein has been labelled as a neuronal apoptosis inhibitor protein (NAIP). A deletion in the (NAIP) domain was identified in persons with Type I, II and III Spinal Muscular Atrophy (SMA) and not in the normal non-SMA population.
Type:
Grant
Filed:
June 20, 1997
Date of Patent:
February 1, 2000
Assignees:
The University of Ottawa, Research Development Corp. of Japan
Inventors:
Alex E. MacKenzie, Robert G. Korneluk, Natalie Roy, Mani S. Mahadevan, Michael McLean, Joh-E Ikeda